| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Friday, November 10, 2017 Still dealing with intense pricing pressure in its key diabetes business, Novo Nordisk is embarking on its latest wave of job cuts. |
|
|
Top Stories Of The Week Monday, November 13, 2017 Novartis has penned a new deal with Homology Medicines as it looks to boost its already impressive R&D work in cell and gene therapy. Monday, November 13, 2017 Pfizer now has a chief operating officer and, potentially, a successor to CEO Ian Read. It's Albert Bourla, who's headed up the company's Innovative Health unit since early 2016. Friday, November 10, 2017 Bucking a growing and depressing trend in biotech, Roivant’s Vivek Ramaswamy is not spinning his company’s Alzheimer’s disease failure in September. Wednesday, November 15, 2017 AstraZeneca is about to find out whether its third-to-market respiratory biologic can stand out from the crowd—and a lower price might just do it. Fasenra, known in the clinic as benralizumab, won FDA approval for a severe type of asthma, and AZ is undercutting its two chief rivals. Monday, November 13, 2017 CRISPR-Cas9 has generated excitement for its potential use in eliminating disease-causing irregularities in DNA, but most systems rely on viral vectors. Scientists at MIT have developed nanoparticles that could eliminate the need to use viruses to edit genes. Wednesday, November 15, 2017 Lupin has been trying for two years to get its plant in Goa, India, up to FDA standards so it can again release new drugs from there. But the Indian drugmaker has a ways to go yet, according to the FDA, which says Lupin seems unable to learn from past mistakes. Friday, November 10, 2017 Roche Diagnostics has entered into a collaboration with a biotech startup. The deal will see Roche work with Inotrem to develop an assay for measuring a biomarker correlated to negative outcomes in septic shock patients. Tuesday, November 14, 2017 It was only August when Merck and GlaxoSmithKline had to deal with a global shortage of their hepatitis B vaccines, and now unexpected demand in the U.S. has sent both companies scrambling to cope with a shortage of hepatitis A shots. Monday, November 13, 2017 Concept Life Sciences’ recent acquisition of Aquila BioMedical has quickly produced a return—an extended contract with Macrophage Pharma to support its preclinical immuno-oncology programs. Resources Sponsored by: Veeva Systems See the results from one of the largest, most in-depth surveys of clinical data management professionals on data management practices, performance, and challenges. Sponsored by: Veeva Systems Gain a complete, real-time view of quality and streamline operations. Incorporate partners into processes for critical oversight and 30% greater efficiency, and transform cross-functional processes like change control. Presented by: DSM Biomedical Discover DSM's Dyneema Purity® membrane, an effective and efficient material to construct stent grafts used in minimally invasive surgeries to treat both cardiovascular and peripheral arterial diseases. Sponsored by: ePharmaSolutions As clinical trials become more complex, safety document distribution to investigative sites has reached the point that demands a solution. Sponsored by: Ashfield Healthcare December 5, 2017 | 2pm EST / 11am PST Join this webinar to learn methods that maintain and build sales momentum despite turnover. Sponsored by: Veeva CROs are leading an industry wide shift to modernize clinical systems and clinical trial processes. | 